Management of inflammatory bowel disease in children: It is time for an individualised approach

Paediatric‐onset inflammatory bowel disease (PO‐IBD) is associated with greater morbidity compared to adult‐onset IBD. However, as not all children with PO‐IBD will have poor outcome and the best management decisions involve weighing risks versus benefit and wishes of patient's and family, we review risk factors of IBD progression in children and summarise rapidly expanding treatment choices, potential drug‐related adverse events and risk minimisation strategies, ending with new treatment paradigms focusing on long‐term goal of intestinal healing. For the purpose of this article, we have outlined the conventional approach, including medications currently licenced and available for use in Australia for paediatric IBD through the Pharmaceutical Benefit Scheme and briefly discuss other promising therapies that are shown to be effective in adults but are undergoing paediatric clinical trials